MMMaria Cristina Montesco

Maria Cristina Montesco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Cristina Montesco has a total of 305 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Tables S1-S3 from BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors

    by Camilla Stagni, Carolina Zamuner, Lisa Elefanti, Tiziana Zanin, Paola Del Bianco, Antonio Sommariva, Alessio Fabozzi, Jacopo Pigozzo, Simone Mocellin, Maria Cristina Montesco, et al.

  • Open Access

    Supplementary Tables S1-S3 from BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors

    by Camilla Stagni, Carolina Zamuner, Lisa Elefanti, Tiziana Zanin, Paola Del Bianco, Antonio Sommariva, Alessio Fabozzi, Jacopo Pigozzo, Simone Mocellin, Maria Cristina Montesco, et al.

    Table S1. Nucleotidic sequences of primers and probes used in the qPCR analyses. Table S2. Detailed description of BRAF copy number (CN) and mutant-allele specific quantification results. Table S3. Analysis of the association between BRAF copy number and mutant allele frequency with best response by Fisher''s exact test.

  • Open Access

    Cost-effectiveness of a melanoma screening programme using whole disease modelling

    by Alessandra Buja, Michele Rivera, Giovanni Girardi, Antonella Vecchiato, Vincenzo Rebba, Elena Pizzo, Vanna Chiarion Sileni, Angelo Claudio Palozzo, Maria Montesco, Manuel Zorzi, et al.

    Objective: To assess the potential impact of a melanoma screening programme, compared with usual care, on direct costs and life expectancy in the era of targeted drugs and cancer immunotherapy. Methods: Using a Whole Disease Model approach, a Markov simulation model with a time horizon of 25 years was devised to analyse the cost-effectiveness of a one-time, general practitioner-based melanoma screening strategy in the population aged over 20, compared with no screening. The study considered the most up-to-date drug therapy and was conducted from the perspective of the Veneto regional healthcare system within the Italian National Health Service. Only direct costs were considered. Sensitivity analyses, both one-way and probabilistic, were performed to identify the parameters with the greatest impact on cost-effectiveness, and to assess the robustness of our model. Results: Over a 25-year time horizon, the screening intervention dominated usual care. The probabilistic sensitivity analyses confirmed the robustness of these findings. The key drivers of the model were the proportion of melanomas detected by the screening procedure and the adherence of the target population to the screening programme. Conclusions: The screening programme proved to be a dominant option compared with usual care. These findings should prompt serious consideration of the design and implementation of a regional or national melanoma screening strategy within a National Health Service.


  • Core needle biopsy of soft tissue tumors, CEUS vs US guided: a pilot study

    by Alessandro Coran, Antonio Di Maggio, Marco Rastrelli, Enrico Alberioli, Shady Attar, Paolo Ortolan, Carlo Bortolanza, Annalisa Tosi, Maria Cristina Montesco, Elisabetta Bezzon, et al.

    The purpose of this study was to evaluate the usefulness of contrast-enhanced ultrasonography (CEUS) in the bioptic sampling of soft tissue tumors (STT) compared with unenhanced ultrasonography alone. This is a prospective longitudinal study of 40 patients subjected to ultrasonography (US)-guided core needle biopsy (CNB) to characterize a suspected STT. Three series of bioptic samplings were carried out on each patient, respectively using unenhanced US alone and CEUS in both the areas of the tumor enhanced or not by the contrast medium. All bioptic samples underwent a histological evaluation and the results were analyzed by comparing the histology of the biopsy with the definitive diagnosis in 15 surgically excised samples. 27 (67.5 %) of the 40 patients completed the entire study procedure; in 19 cases (70.3 %) the three bioptic samplings gave unanimous results, also when compared to the surgical specimen; in seven cases (25.9 %) use of CEUS allowed to obtain additional or more accurate information about the mass in question, compared to simple US guidance without contrast; in one patient (3.7 %) sampling obtained using unenhanced ultrasonography guidance and in the areas enhanced by the contrast agent had precisely the same results of the surgical specimen. CEUS, due to its ability to evaluate microvascular areas, has proven to be a promising method in guiding bioptic sampling of soft tissue tumor, directing the needle to the most significant areas of the tumor. Given the small number of patients evaluated in our study, to achieve statistically significant results, it would be appropriate to obtain a larger sample size, since the very first results seem to be encouraging and to justify the increase of the population. Lo scopo di questo studio è stato quello di valutare l’utilità dell’ecografia conmdc (CEUS) rispetto alla ecografia tradizionale, nel prelievo bioptico dei tumori dei tessuti molli (STT). si tratta di uno studio longitudinale prospettico di 40 pazienti sottoposti ad ago-biopsia ecoguidata (US-CNB) per la caratterizzazione di un STT sospetto. Sono stati prelevati 3 campioni bioptici su ogni paziente, utilizzando ecografia b-mode e CEUS sia nelle aree del tumore non evidenziate dal mezzo di contrasto che in quelle dotate di contrast-enhancement. Tutti i campioni bioptici sono stati sottoposti a valutazione istologica e sono stati analizzati i risultati confrontando l’istologico della biopsia con i 15 campioni asportati chirurgicamente, con diagnosi definitiva. 27 (67,5%) dei 40 pazienti hanno completato l’intera procedura di studio; in 19 casi (70,3%) i tre campioni bioptici hanno dato risultati unanimi, anche rispetto al modello chirurgico; in 7 casi (25,9%) l’uso della CEUS ha permesso di ottenere informazioni supplementari, o più precise, circa la massa in questione, rispetto al semplice esame ecografico senza mezzo di contrasto; in 1 paziente (3,7%) i campioniottenuti usando sia l’ecografia tradizionale che quella con contrasto sono risultati esattamente corrispondenti ai campioni chirurgici. la CEUS, grazie alla sua capacità di valutare la microvascolarizzazione, ha dimostrato di essere un metodo promettente nel guidare il prelievo bioptico negli STT, dirigendo l’ago nelle zone più caratteristiche del tumore. Secondo i risultati di questo studio pilota, sarebbe pertanto opportuno esaminare un maggior numero di pazienti per confermare le potenzialità della metodica.


  • Atypical Spitz tumors in patients younger than 18 years

    by Daniela Massi, Carlo Tomasini, Rebecca Senetta, Milena Paglierani, Francesca Salvianti, Maria Elena Errico, Vittoria Donofrio, Paola Collini, Gabrina Tragni, Angela Rita Sementa, et al.


  • Open Access

    Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases

    by Elisa Zanardi, Marco Maruzzo, Maria C. Montesco, Anna Roma, Marco Rastrelli, Umberto Basso

    Trabectedin is an alkylating agent registered in Europe for the treatment of advanced metastatic soft-tissue sarcomas, whose activity has been documented mainly in liposarcomas or leiomyosarcomas. Here, we report the response achieved in a patient with lung metastases from synovial sarcoma. A man with a large synovial sarcoma of the axilla underwent three cycles of neoadjuvant epirubicin+ifosfamide before complete excision, followed by three additional cycles of chemotherapy and radiotherapy. After 14 months, bilateral lung metastases appeared and were first treated with a prolonged 14-day continuous infusion of high-dose ifosfamide without response, and then with second-line trabectedin. A partial radiological response was achieved; dosage was reduced to 1.1 mg/m because of mild asthenia, grade 3 neutropenia, grade 3 nausea and vomiting, and reversible transaminase elevation. After 9 months of treatment, the lung nodules progressed, the patient received sorafenib, but further progressed and died 19 months after the first appearance of lung metastases. Trabectedin was the only drug that led to a radiological response in this patient with synovial sarcoma, despite being administered at 75% of the standard dose because of dose-limiting nausea and vomiting, in line with more recent data demonstrating activity in translocated sarcomas. We believe that trabectedin represents an attractive option for the treatment of metastatic synovial sarcoma and further clinical studies are warranted.


  • Pelvic lymph node status prediction in melanoma patients with inguinal lymph node metastasis

    by Sandro Pasquali, Simone Mocellin, Francesco Bigolin, Antonella Vecchiato, Maria C. Montesco, Antonio Di Maggio, Carlo R. Rossi

    The extent of the groin lymph node (LN) dissection for melanoma is still being debated, particularly in the case of micrometastasis (sentinel lymph node positive). We tested the predictive values of the criteria for pelvic dissection currently suggested by national guidelines (number of positive inguinal LN, Cloquet's LN status, and preoperative computed tomographic scan) and the inguinal lymph node ratio (LNR, the ratio between metastatic and excised LNs) to identify patients with pelvic metastasis. We analyzed the predictive values of the above-mentioned criteria in 157 patients who underwent an ilioinguinal dissection, with a focus on their negative predictive values (NPV), which might help identify low-risk patients who might safely avoid pelvic dissection, pelvic dissection reduction, and error rate. Forty-four (26.7%) patients had pelvic LN metastasis. In patients with micrometastasis (17.3% had pelvic LN metastasis), LNR less than 0.1 and Cloquet's LN status achieved clinically relevant NPV (95.7 and 95.5%, respectively) and pelvic dissection reduction (38.4 and 84.6%, respectively), whereas the error rate was 1.7 and 3.0%, respectively. Lower NPVs were observed for number of positive inguinal LNs (88.6%) and computed tomographic scan (78.4%). Accuracy was enhanced when these criteria were considered in multivariable models. In patients with macrometastasis (36.8% had pelvic LN metastasis), LNR and current selection criteria achieved low NPVs and a high error rate. Avoiding pelvic dissection may be safe in sentinel lymph node-positive patients with LNR less than 0.1. The prediction of pelvic metastasis seems to be less accurate for patients with clinically positive LNs


  • Lymphatic and blood vasculature in primary cutaneous melanomas of the scalp and neck

    by Sandro Pasquali, Maria Cristina Montesco, Chiara Ginanneschi, Gianna Baroni, Clelia Miracco, Carmelo Urso, Fabio Mele, Anna Rita Lombardi, Pietro Quaglino, Laura Cattaneo, et al.

    Background Scalp/neck melanomas have a poor prognosis, possibly because of a rich vascular supply that prompts tumor cells' dissemination. Methods We compared the accuracy of immunohistochemical (IHC) staining with morphology for the identification of lymphovascular invasion in 156 scalp/neck melanomas. We then analyzed the association of vessel invasion and density with pathological features and survival. Results IHC‐detected lymphatic vessel invasion (LVI) and blood vessel invasion (BVI) were identified in 34.6% and 13.5% of cases, respectively. IHC increased the LVI/BVI detection compared to morphology (40.4% vs 16.6%; p < .001). The degree of peritumoral and intratumoral blood vessel density (BVD) was greater than lymphatic vessel density (LVD). Ulceration was the only factor independently associated with intratumoral (p = .029) and peritumoral (p = .047) BVD. Tumor thickness was the only independent predictor of survival (p = .002). Conclusion IHC allows accurate assessment of lymphovascular invasion in scalp/neck melanomas. In these tumors, we observed a high incidence of BVI, which deserves further investigations. © 2014 Wiley Periodicals, Inc. Head Neck 37: 1596–1602, 2015


  • Open Access

    Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)

    by Francesca Bergamo, Marco Maruzzo, Umberto Basso, Maria Cristina Montesco, Vittorina Zagonel, Enrico Gringeri, Umberto Cillo

    Perivascular epithelioid cell tumors (PEComas) are rare soft-tissue tumors with an extremely heterogeneous clinical behavior. They may arise in different organs and may behave indolently or sometimes metastasize with different grades of biological aggressiveness. We report the case of a young woman with a primary inoperable PEComa of the liver with malignant histological features. Since the mTOR pathway is often altered in PEComas and responses have been reported with mTOR-inhibitors such as sirolimus or temsirolimus, we decided to start a neoadjuvant treatment with sirolimus. The patient tolerated the treatment fairly well and after 8 months a favorable tumor shrinkage was obtained. The patient then stopped sirolimus and 2 weeks later underwent partial liver resection, with complete clinical recovery and normal liver function. The histological report confirmed a malignant PEComa with vascular invasion and negative margins. Then 6 additional months of post-operative sirolimus treatment were administered, followed by regular radiological follow-up. For patients with a large and histologically aggressive PEComa, we think that neoadjuvant treatment with mTOR-inhibitor sirolimus may be considered to facilitate surgery and allow early control of a potentially metastatic disease. For selected high-risk patients, the option of adjuvant treatment may be discussed.


    • 1 September 2013
      • Vol. 33  (9) , 3989-94

    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal sarcomatosis: long-term outcome from a single institution experience.

    by Antonio Sommariva, Sandro Pasquali, Paolo Del Fiore, Maria Montesco, Pierluigi Pilati, Marco Rastrelli, Jude Niba, Donato Nitti, Carlo Riccardo Rossi

    We assessed the long-term local disease-free survival (LDFS) and overall survival (OS) of patients with peritoneal sarcomatosis (PS) uniformly-treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS plus HIPEC). Retrospective data of 15 patients who underwent CS plus HIPEC for PS were extracted from a prospectively collected database. DFS and OS were calculated from the date of CS plus HIPEC to local relapse and death, respectively. After a median follow-up of 28 months (range=4-144 months), median LDFS was 15 months (95% Confidence Interval CI=1-40 months). Median OS was 27 (95% CI=24.7-29.3) months. Long-term OS was achieved in three patients (20%) and ranged between 93 and 144 months. Female sex was the only factor significantly correlated with a greater LDFS (p=0.018). Patients with PS of visceral origin seem at lower risk of recurrence and death but the difference did not prove significant. In our series, long-term survival was achieved in 20% of patients after CS plus HIPEC, with a benefit in female patients with PS of visceral origin. The impact of HIPEC after radical surgery for PS remains questionable and still has to be further evaluated in large cooperative multi-institutional studies.